Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 1
2005 1
2006 1
2007 2
2008 1
2009 3
2010 3
2011 2
2012 2
2015 2
2016 2
2017 2
2018 3
2019 6
2020 4
2021 4
2022 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.
Ascierto PA, Casula M, Bulgarelli J, Pisano M, Piccinini C, Piccin L, Cossu A, Mandalà M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, Richtig E, Fierro MT, Lebbe C, Helgadottir H, Queirolo P, Spagnolo F, Tucci M, Del Vecchio M, Cao MG, Minisini AM, De Placido S, Sanmamed MF, Mallardo D, Paone M, Vitale MG, Melero I, Grimaldi AM, Giannarelli D, Dummer R, Sileni VC, Palmieri G. Ascierto PA, et al. Among authors: casula m. Nat Commun. 2024 Jan 2;15(1):146. doi: 10.1038/s41467-023-44475-6. Nat Commun. 2024. PMID: 38167503 Free PMC article. Clinical Trial.
BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors.
Mandalà M, Palmieri G, Ludovini V, Baglivo S, Marasciulo F, Castiglione F, Gili A, Osella Abate S, Rubatto M, Senetta R, Avallone G, Ribero S, Romano L, Pimpinelli N, de Giorgi V, Roila F, Pisano M, Casula M, Manca A, Sini MC, Massi D, Quaglino P; Italian Melanoma Intergroup (IMI). Mandalà M, et al. Among authors: casula m. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):1991-1998. doi: 10.1111/jdv.19281. Epub 2023 Jun 27. J Eur Acad Dermatol Venereol. 2023. PMID: 37335879
Comparison between Three Different Techniques for the Detection of EGFR Mutations in Liquid Biopsies of Patients with Advanced Stage Lung Adenocarcinoma.
Casula M, Pisano M, Paliogiannis P, Colombino M, Sini MC, Zinellu A, Santeufemia D, Manca A, Casula S, Tore S, Lobrano R, Sardinian Lung Cancer Study Group, Cossu A, Palmieri G. Casula M, et al. Int J Mol Sci. 2023 Mar 29;24(7):6410. doi: 10.3390/ijms24076410. Int J Mol Sci. 2023. PMID: 37047382 Free PMC article.
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients.
Mariani S, Puzzoni M, Giampieri R, Ziranu P, Pusceddu V, Donisi C, Persano M, Pinna G, Cimbro E, Parrino A, Spanu D, Pretta A, Lai E, Liscia N, Lupi A, Giglio E, Palomba G, Casula M, Pisano M, Palmieri G, Scartozzi M. Mariani S, et al. Among authors: casula m. Front Oncol. 2022 Apr 21;12:852583. doi: 10.3389/fonc.2022.852583. eCollection 2022. Front Oncol. 2022. PMID: 35530345 Free PMC article.
Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study.
Paliogiannis P, Colombino M, Sini MC, Manca A, Casula M, Palomba G, Pisano M, Doneddu V, Zinellu A, Santeufemia D; Sardinian Lung Cancer (SLC) Study Group; Sotgiu G, Cossu A, Palmieri G. Paliogiannis P, et al. Among authors: casula m. BMC Pulm Med. 2022 Jan 10;22(1):32. doi: 10.1186/s12890-021-01803-0. BMC Pulm Med. 2022. PMID: 35012520 Free PMC article.
The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something?
Ottaviano M, Giunta EF, Rescigno P, Pereira Mestre R, Marandino L, Tortora M, Riccio V, Parola S, Casula M, Paliogiannis P, Cossu A, Vogl UM, Bosso D, Rosanova M, Mazzola B, Daniele B, Palmieri G, Palmieri G. Ottaviano M, et al. Among authors: casula m. Int J Mol Sci. 2021 Jul 2;22(13):7160. doi: 10.3390/ijms22137160. Int J Mol Sci. 2021. PMID: 34281219 Free PMC article. Review.
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study.
Calabrò L, Rossi G, Morra A, Rosati C, Cutaia O, Daffinà MG, Altomonte M, Di Giacomo AM, Casula M, Fazio C, Palmieri G, Giannarelli D, Covre A, Maio M. Calabrò L, et al. Among authors: casula m. Lancet Respir Med. 2021 Sep;9(9):969-976. doi: 10.1016/S2213-2600(21)00043-6. Epub 2021 Apr 9. Lancet Respir Med. 2021. PMID: 33844995 Free PMC article.
Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI).
Vanni I, Casula M, Pastorino L, Manca A, Dalmasso B, Andreotti V, Pisano M, Colombino M; Italian Association for Cancer Research (AIRC) Study Group; Pfeffer U, Tanda ET, Rozzo C, Paliogiannis P, Cossu A, Ghiorzo P, Palmieri G; Italian Melanoma Intergroup (IMI). Vanni I, et al. Among authors: casula m. Diagn Pathol. 2020 Dec 14;15(1):143. doi: 10.1186/s13000-020-01052-5. Diagn Pathol. 2020. PMID: 33317587 Free PMC article.
47 results